Karolinska Development AB represents a value-driven corporate philosophy focused on enabling the commercialization of innovative life science technologies. The company is dedicated to improving human health and actively supports the development of breakthrough therapies and medical innovations. Karolinska Development AB strives for long-term financial success while prioritizing ethical and sustainable practices. By identifying promising projects and providing strategic guidance, funding, and industry expertise, the company accelerates the growth of healthcare companies and fosters collaborations within the life science sector. Karolinska Development AB's commitment to driving scientific advancements and delivering shareholder value positions it as a leading player in the industry.

Karolinska Development AB, a renowned Swedish life science investment company, primarily operates in Sweden. With its headquarters situated in Stockholm, the company focuses on identifying and developing innovations within the healthcare sector. Karolinska Development AB plays a crucial role in supporting the commercialization and growth of early-stage life science companies originating from Sweden's prestigious Karolinska Institutet. With an extensive network of contacts and partnerships, Karolinska Development AB drives advancements in the field of biomedicine, primarily within Sweden's vibrant life science ecosystem.

Karolinska Development AB, a leading Nordic life science investment company, has achieved several significant milestones. The company has successfully supported the growth of numerous innovative healthcare companies and fostered collaborations with top academic institutions. Karolinska Development has enabled the development and commercialization of several breakthrough therapies and medical technologies, addressing critical unmet medical needs. Its extensive portfolio encompasses companies focusing on various therapeutic areas, including oncology, rare diseases, and regenerative medicine. With its strategic investments and valuable expertise, Karolinska Development continues to play a vital role in advancing the life sciences industry and improving patient outcomes.

Karolinska Development AB is a leading investment company in the field of life sciences. Established in 2003, the company focuses on identifying and developing innovative pharmaceutical products and medical technologies. As a subsidiary of Karolinska Institutet Holding AB, Karolinska Development collaborates with academia, top-notch experts, and industry stakeholders to bring promising research and commercialize breakthrough innovations. The company's portfolio includes a diverse range of investments in companies involved in drug development, medical devices, diagnostics, and digital health solutions. Karolinska Development aims to leverage its extensive network and knowledge to drive the growth and success of its portfolio companies in the global healthcare market.

The main competitors of Karolinska Development AB in the market include other biotechnology and pharmaceutical companies focusing on innovation and drug development. Some notable competitors include AstraZeneca, Novartis, Pfizer, GlaxoSmithKline, and Johnson & Johnson. These companies compete in the same industry, striving to bring new drugs and therapies to the market. Karolinska Development AB sets itself apart through its expertise in evaluating and identifying promising early-stage life science opportunities.

Karolinska Development AB is primarily active in the life sciences and healthcare industries.

Karolinska Development AB operates as a life sciences investment company. The company's business model focuses on identifying, developing, and commercializing innovative healthcare technologies originating from leading academic research institutions in the Nordic region. Karolinska Development AB aims to support the growth of these projects by providing expertise, funding, and strategic guidance. By actively participating in the development process, the company strives to maximize the potential value of its portfolio of companies. Through partnerships and collaborations, Karolinska Development AB aims to advance medical innovations that address significant unmet medical needs, ultimately benefiting both patients and investors.

Raportul Karolinska Development preț/beneficiu este -11,94.

Raportul Karolinska Development preț/vânzări este 159,52.

Scorul de calitate AlleAktien nu poate fi calculat în prezent pentru Karolinska Development.

Cifra de afaceri a așteptată Karolinska Development este de 2,04 milioane SEK.

Profitul așteptată Karolinska Development este -27,26 milioane SEK.

Karolinska Development AB specializes in the development of medications and medical technologies. The company's business model is based on building partnerships with promising startups and research institutions in the healthcare sector and supporting them in bringing their products and technologies to market. The company operates in four strategic business areas: company formation, technology development, product development, and management consulting. Karolinska Development AB aims to become a leading company in the healthcare industry and promote the development of medications and medical technologies.

Karolinska Development distribuie un dividend de 0 SEK în plăți anuale.

Dividenda nu poate fi calculată în prezent pentru Karolinska Development sau compania nu distribuie dividende.

Codul ISIN pentru Karolinska Development este SE0002190926.

Codul WKN al Karolinska Development este A0M84G.

Ticker-ul pentru Karolinska Development este KDEV.ST.

În ultimele 12 luni, Karolinska Development a plătit un dividend în valoare de . Aceasta corespunde unei randamente a dividendului de aproximativ . Pentru următoarele 12 luni, Karolinska Development va plăti probabil un dividend de 0 SEK.

Randamentul dividendelor pentru Karolinska Development este în prezent de .

Karolinska Development plătește un dividend trimestrial. Acesta este distribuit în lunile .

Karolinska Development a plătit dividende în fiecare an, în ultimii 0 ani.

Pentru următoarele 12 luni se așteaptă dividende în valoare de 0 SEK. Acest lucru corespunde unei randamente a dividendelor de 0 %.

Karolinska Development este atribuit sectorului 'Sănătate'.

Pentru a primi ultimul dividend de Karolinska Development de la 02.11.2024 în valoare de 0 SEK, trebuia să deții acțiunea în portofoliu înainte de ziua Ex-Tag de pe 02.11.2024.

Ultima plată a dividendului a fost efectuată la 02.11.2024.

În anul 2023, Karolinska Development a distribuit 0 SEK sub formă de dividende.

Dividendele de la Karolinska Development sunt distribuite în SEK.